assessing risk predictors for CINV
using a large sample size 10 (for
further information, please see the
dedicated chapter on risk factors in
this pocket guide).
International antiemetic
guidelines
Several international societies have
been developing and disseminating
antiemetic guidelines related
to cancer treatments since
the late 1990s. Among them,
the most prominent are the
antiemetic guidelines produced
by the Multinational Association
of Supportive Care in Cancer
(MASCC; www.mascc.org), the
European Society of Medical
Oncology (ESMO; www.esmo.org);
18 | 2019 | hospitalpharmacyeurope.com
with MASCC and ESMO working
together in developing antiemetic
guidelines and publishing the
second combined update in
2016, 11 the American Society
of Clinical Oncology (ASCO) 12
(www.asco.org), and the National
Comprehensive Cancer Network
(NCCN) in the USA (www.nccn.
org). 13 The key recommendations
are almost the same across these
guidelines, although there are
subtle differences between them.
Carboplatin is considered as both
HEC and MEC, depending on the
guidelines, but all recommend
the addition of an NK 1 RA to
prevent CINV in this case. For
HEC (including anthracycline plus
cyclophosphamide (AC)-based